Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients

  • Home
  • 2019
  • September
  • 28
  • Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients

Original Source

On September 28, 2019

Post navigation

Previous PostNorwegian Cruise Line Partners with JUSTĀ® Goods, Inc. to Eliminate Single-Use Plastic Bottles Across Fleet
Next PostBristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer

Related Post

May 25, 2022
  • Business News

Boeing, NASA Complete First Starliner Space Station Flight Test

May 25, 2022
  • Business News

Northrop Grumman Australia Announces Tech Showcase Winners

May 25, 2022
  • Business News

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219